{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:56:25Z","timestamp":1789757785466,"version":"4.0.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11311-6","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:18:22Z","timestamp":1754327902000},"page":"3009-3030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recent advances in piperazine derivatives as antibacterial agents: a comprehensive review (2020\u20132024)"],"prefix":"10.1007","volume":"30","author":[{"given":"Kripa","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moksh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khyati","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afzal","family":"Nagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"11311_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s000180050018","volume":"56","author":"W Ziebuhr","year":"1999","unstructured":"Ziebuhr W, Ohlsen K, Karch H et al (1999) Evolution of bacterial pathogenesis. Cell Mol Life Sci 56:719\u2013728. https:\/\/doi.org\/10.1007\/s000180050018","journal-title":"Cell Mol Life Sci"},{"key":"11311_CR2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/35021219","volume":"406","author":"C Walsh","year":"2000","unstructured":"Walsh C (2000) Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775\u2013781. https:\/\/doi.org\/10.1038\/35021219","journal-title":"Nature"},{"key":"11311_CR3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.257.5073.1064","volume":"257","author":"HC Neu","year":"1992","unstructured":"Neu HC (1992) The crisis in antibiotic resistance. Science 257:1064\u20131073. https:\/\/doi.org\/10.1126\/science.257.5073.1064","journal-title":"Science"},{"key":"11311_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00239-019-09914-3","volume":"88","author":"E Christaki","year":"2020","unstructured":"Christaki E, Marcou M, Tofarides A (2020) Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. J Mol Evol 88:26\u201340. https:\/\/doi.org\/10.1007\/s00239-019-09914-3","journal-title":"J Mol Evol"},{"key":"11311_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/antibiotics10050593","volume":"10","author":"MF Varela","year":"2021","unstructured":"Varela MF, Stephen J, Lekshmi M et al (2021) Bacterial resistance to antimicrobial agents. Antibiotics 10:593. https:\/\/doi.org\/10.3390\/antibiotics10050593","journal-title":"Antibiotics"},{"key":"11311_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/antibiotics9050221","volume":"9","author":"MA Morsy","year":"2020","unstructured":"Morsy MA, Ali EM, Kandeel M et al (2020) Screening and molecular docking of novel benzothiazole derivatives as potential antimicrobial agents. Antibiotics 9:221. https:\/\/doi.org\/10.3390\/antibiotics9050221","journal-title":"Antibiotics"},{"key":"11311_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.micpath.2018.07.025","volume":"123","author":"X Zhang","year":"2018","unstructured":"Zhang X, Manukumar HM, Rakesh KP et al (2018) Role of BP*C@AgNPs in Bap-dependent multicellular behavior of clinically important methicillin-resistant Staphylococcus aureus (MRSA) biofilm adherence: a key virulence study. Microb Pathog 123:275\u2013284. https:\/\/doi.org\/10.1016\/j.micpath.2018.07.025","journal-title":"Microb Pathog"},{"key":"11311_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.micres.2018.05.002","volume":"212","author":"X Zhang","year":"2018","unstructured":"Zhang X, Marichannegowda MH, Rakesh KP, Qin H-L (2018) Master mechanisms of Staphylococcus aureus: consider its excellent protective mechanisms hindering vaccine development! Microbiol Res 212:59\u201366. https:\/\/doi.org\/10.1016\/j.micres.2018.05.002","journal-title":"Microbiol Res"},{"key":"11311_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1021\/acscombsci.8b00088","volume":"20","author":"KP Rakesh","year":"2018","unstructured":"Rakesh KP, Marichannegowda MH, Srivastava S et al (2018) Combating a master manipulator: Staphylococcus aureus immunomodulatory molecules as targets for combinatorial drug discovery. ACS Comb Sci 20:681\u2013693. https:\/\/doi.org\/10.1021\/acscombsci.8b00088","journal-title":"ACS Comb Sci"},{"key":"11311_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2019.100473","volume":"18","author":"EO Ogunsona","year":"2020","unstructured":"Ogunsona EO, Muthuraj R, Ojogbo E et al (2020) Engineered nanomaterials for antimicrobial applications: a review. Appl Mater Today 18:100473. https:\/\/doi.org\/10.1016\/j.apmt.2019.100473","journal-title":"Appl Mater Today"},{"key":"11311_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S1473-3099(18)30714-X","volume":"19","author":"BG Mitchell","year":"2019","unstructured":"Mitchell BG, Hall L, White N et al (2019) An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. Lancet Infect Dis 19:410\u2013418. https:\/\/doi.org\/10.1016\/S1473-3099(18)30714-X","journal-title":"Lancet Infect Dis"},{"key":"11311_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cmi.2019.09.015","volume":"26","author":"J Vila","year":"2020","unstructured":"Vila J, Moreno-Morales J, Ballest\u00e9-Delpierre C (2020) Current landscape in the discovery of novel antibacterial agents. Clin Microbiol Infect 26:596\u2013603. https:\/\/doi.org\/10.1016\/j.cmi.2019.09.015","journal-title":"Clin Microbiol Infect"},{"key":"11311_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/antibiotics8040254","volume":"8","author":"MM D\u2019Andrea","year":"2019","unstructured":"D\u2019Andrea MM, Fraziano M, Thaller MC, Rossolini GM (2019) The urgent need for novel antimicrobial agents and strategies to fight antibiotic resistance. Antibiotics 8:254. https:\/\/doi.org\/10.3390\/antibiotics8040254","journal-title":"Antibiotics"},{"key":"11311_CR14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41591-020-0919-z","volume":"26","author":"BW Haak","year":"2020","unstructured":"Haak BW, Wiersinga WJ (2020) Uncovering hidden antimicrobial resistance patterns within the hospital microbiome. Nat Med 26:826\u2013828. https:\/\/doi.org\/10.1038\/s41591-020-0919-z","journal-title":"Nat Med"},{"key":"11311_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1134\/S1068162018020036","volume":"44","author":"KP Rakesh","year":"2018","unstructured":"Rakesh KP, Ramesh S, Shivakumar GDC (2018) Effect of low charge and high hydrophobicity on antimicrobial activity of the Quinazolinone-peptide conjugates. Russ J Bioorganic Chem 44:158\u2013164. https:\/\/doi.org\/10.1134\/S1068162018020036","journal-title":"Russ J Bioorganic Chem"},{"key":"11311_CR16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0140-6736(16)31425-8","volume":"388","author":"L Matthiessen","year":"2016","unstructured":"Matthiessen L, Bergstr\u00f6m R, Dustdar S et al (2016) Increased momentum in antimicrobial resistance research. Lancet 388:865. https:\/\/doi.org\/10.1016\/S0140-6736(16)31425-8","journal-title":"Lancet"},{"key":"11311_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41579-020-0348-5","volume":"18","author":"C Nathan","year":"2020","unstructured":"Nathan C (2020) Resisting antimicrobial resistance. Nat Rev Microbiol 18:259\u2013260. https:\/\/doi.org\/10.1038\/s41579-020-0348-5","journal-title":"Nat Rev Microbiol"},{"key":"11311_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/femsre\/fux016","volume":"41","author":"E Banin","year":"2017","unstructured":"Banin E, Hughes D, Kuipers OP (2017) Editorial: Bacterial pathogens, antibiotics and antibiotic resistance. FEMS Microbiol Rev 41:450\u2013452. https:\/\/doi.org\/10.1093\/femsre\/fux016","journal-title":"FEMS Microbiol Rev"},{"key":"11311_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/cid\/ciaa773","volume":"72","author":"R Nieuwlaat","year":"2021","unstructured":"Nieuwlaat R, Mbuagbaw L, Mertz D et al (2021) Coronavirus disease 2019 and antimicrobial resistance: parallel and interacting health emergencies. Clin Infect Dis 72:1657\u20131659. https:\/\/doi.org\/10.1093\/cid\/ciaa773","journal-title":"Clin Infect Dis"},{"key":"11311_CR20","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1021\/acsanm.1c03891","volume":"5","author":"AI Ribeiro","year":"2022","unstructured":"Ribeiro AI, Dias AM, Zille A (2022) Synergistic effects between metal nanoparticles and commercial antimicrobial agents: a review. ACS Appl Nano Mater 5:3030\u20133064. https:\/\/doi.org\/10.1021\/acsanm.1c03891","journal-title":"ACS Appl Nano Mater"},{"key":"11311_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers M, Wright GD (2019) Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol 17:141\u2013155. https:\/\/doi.org\/10.1038\/s41579-018-0141-x","journal-title":"Nat Rev Microbiol"},{"key":"11311_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bioorg.2018.08.024","volume":"81","author":"C Li","year":"2018","unstructured":"Li C, Sridhara MB, Rakesh KP et al (2018) Multi-targeted dihydrazones as potent biotherapeutics. Bioorg Chem 81:389\u2013395. https:\/\/doi.org\/10.1016\/j.bioorg.2018.08.024","journal-title":"Bioorg Chem"},{"key":"11311_CR23","doi-asserted-by":"crossref","unstructured":"Mahira S, Jain A, Khan W, Domb AJ (2019) Antimicrobial Materials\u2014An Overview. In: Antimicrobial Materials for Biomedical Applications. The Royal Society of Chemistry, pp 1\u201337","DOI":"10.1039\/9781788012638-00001"},{"key":"11311_CR24","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1039\/C7RA13661G","volume":"8","author":"KP Rakesh","year":"2018","unstructured":"Rakesh KP, Vivek HK, Manukumar HM et al (2018) Promising bactericidal approach of dihydrazone analogues against bio-film forming Gram-negative bacteria and molecular mechanistic studies. RSC Adv 8:5473\u20135483. https:\/\/doi.org\/10.1039\/C7RA13661G","journal-title":"RSC Adv"},{"key":"11311_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.128402","volume":"256","author":"K Pakeeraiah","year":"2024","unstructured":"Pakeeraiah K, Mal S, Mahapatra M et al (2024) Schematic-portfolio of potent anti-microbial scaffolds targeting DNA gyrase: unlocking ways to overcome resistance. Int J Biol Macromol 256:128402. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.128402","journal-title":"Int J Biol Macromol"},{"key":"11311_CR26","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1055\/s-0036-1589491","volume":"49","author":"K Gettys","year":"2017","unstructured":"Gettys K, Ye Z, Dai M (2017) Recent advances in piperazine synthesis. Synthesis 49:2589\u20132604. https:\/\/doi.org\/10.1055\/s-0036-1589491","journal-title":"Synthesis"},{"key":"11311_CR27","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/pat.4592","volume":"30","author":"MD Jalageri","year":"2019","unstructured":"Jalageri MD, Puttaiahgowda YM, Parambil AM, Varadavenkatesan T (2019) Synthesis and fabrication of highly functionalized Jeffamine antimicrobial polymeric coating. Polym Adv Technol 30:1616\u20131627. https:\/\/doi.org\/10.1002\/pat.4592","journal-title":"Polym Adv Technol"},{"key":"11311_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/app.47521","author":"MD Jalageri","year":"2019","unstructured":"Jalageri MD, Malgar Puttaiahgowda Y, Parambil AM, Kulal A (2019) Design of multifunctionalized piperazine polymer and its activity toward pathogenic microorganisms. J Appl Polym Sci. https:\/\/doi.org\/10.1002\/app.47521","journal-title":"J Appl Polym Sci"},{"key":"11311_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ilar.46.4.352","volume":"46","author":"WC Campbell","year":"2005","unstructured":"Campbell WC (2005) Serendipity and new drugs for infectious disease. ILAR J 46:352\u2013356. https:\/\/doi.org\/10.1093\/ilar.46.4.352","journal-title":"ILAR J"},{"key":"11311_CR30","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1136\/bmj.1.1746.1291","volume":"1","author":"J Gordon","year":"1894","unstructured":"Gordon J (1894) A contribution to the study of piperazine. BMJ 1:1291\u20131294. https:\/\/doi.org\/10.1136\/bmj.1.1746.1291","journal-title":"BMJ"},{"key":"11311_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.procbio.2023.10.024","volume":"135","author":"Y Hu","year":"2023","unstructured":"Hu Y, Liu Z, Zha G et al (2023) Triazole derivatives as potential antifungal agents: a structure-activity relationship (SAR) studies. Process Biochem 135:102\u2013118. https:\/\/doi.org\/10.1016\/j.procbio.2023.10.024","journal-title":"Process Biochem"},{"key":"11311_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106353","volume":"132","author":"Y Yi","year":"2023","unstructured":"Yi Y, Yang S, Liu Y et al (2023) Antibiotic resistance and drug modification: synthesis, characterization and bioactivity of newly modified potent pleuromutilin derivatives with a substituted piperazine moiety. Bioorg Chem 132:106353. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106353","journal-title":"Bioorg Chem"},{"key":"11311_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114704","volume":"243","author":"L Akl","year":"2022","unstructured":"Akl L, Abd El-Hafeez AA, Ibrahim TM et al (2022) Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer. Eur J Med Chem 243:114704. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114704","journal-title":"Eur J Med Chem"},{"key":"11311_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2024.2436554","author":"H Patel","year":"2024","unstructured":"Patel H, Nagani A, Patel M et al (2024) Design, synthesis and biological evaluation of some imidazo[1,2- a ]pyridine derivatives as anti-tubercular agents: an in silico \u2013 in vitro approach. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2024.2436554","journal-title":"J Biomol Struct Dyn"},{"key":"11311_CR35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s11030-024-10927-4","volume":"29","author":"A Nagani","year":"2025","unstructured":"Nagani A, Shah M, Patel S et al (2025) Unveiling piperazine-quinoline hybrids as potential multi-target directed anti-Alzheimer\u2019s agents: design, synthesis and biological evaluation. Mol Divers 29:1453\u20131478. https:\/\/doi.org\/10.1007\/s11030-024-10927-4","journal-title":"Mol Divers"},{"key":"11311_CR36","doi-asserted-by":"publisher","first-page":"15213","DOI":"10.1039\/D1RA00341K","volume":"11","author":"MD Jalageri","year":"2021","unstructured":"Jalageri MD, Nagaraja A, Puttaiahgowda YM (2021) Piperazine based antimicrobial polymers: a review. RSC Adv 11:15213\u201315230. https:\/\/doi.org\/10.1039\/D1RA00341K","journal-title":"RSC Adv"},{"key":"11311_CR37","doi-asserted-by":"publisher","first-page":"31633","DOI":"10.1039\/D4RA05756B","volume":"14","author":"K Pakeeraiah","year":"2024","unstructured":"Pakeeraiah K, Swain PP, Sahoo A et al (2024) Multimodal antibacterial potency of newly designed and synthesized Schiff\u2019s\/Mannich based coumarin derivatives: potential inhibitors of bacterial DNA gyrase and biofilm production. RSC Adv 14:31633\u201331647. https:\/\/doi.org\/10.1039\/D4RA05756B","journal-title":"RSC Adv"},{"key":"11311_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107931","volume":"153","author":"M Shah","year":"2024","unstructured":"Shah M, Parmar R, Patel K, Nagani A (2024) Indole-based COX-2 inhibitors: a decade of advances in inflammation, cancer, and Alzheimer\u2019s therapy. Bioorg Chem 153:107931. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107931","journal-title":"Bioorg Chem"},{"key":"11311_CR39","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/cmdc.202100045","volume":"16","author":"RR Kumar","year":"2021","unstructured":"Kumar RR, Sahu B, Pathania S et al (2021) Piperazine, a key substructure for antidepressants: its role in developments and structure-activity relationships. ChemMedChem 16:1878\u20131901. https:\/\/doi.org\/10.1002\/cmdc.202100045","journal-title":"ChemMedChem"},{"key":"11311_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2020.100067","volume":"2","author":"BJ Ullas","year":"2020","unstructured":"Ullas BJ, Rakesh KP, Shivakumar J et al (2020) Multi-targeted quinazolinone-Schiff\u2019s bases as potent bio-therapeutics. Results Chem 2:100067. https:\/\/doi.org\/10.1016\/j.rechem.2020.100067","journal-title":"Results Chem"},{"key":"11311_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5155\/eurjchem.6.3.254-260.1233","volume":"6","author":"KP Rakesh","year":"2015","unstructured":"Rakesh KP, Ramesh S, Kumar HM et al (2015) Quinazolinones linked amino acids derivatives as a new class of promising antimicrobial, antioxidant and anti-inflammatory agents. Eur J Chem 6:254\u2013260. https:\/\/doi.org\/10.5155\/eurjchem.6.3.254-260.1233","journal-title":"Eur J Chem"},{"key":"11311_CR42","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/0002-9343(89)90010-7","volume":"87","author":"LM Fisher","year":"1989","unstructured":"Fisher LM, Lawrence JM, Josty IC et al (1989) Ciprofloxacin and the fluoroquinolones. Am J Med 87:S2\u2013S8. https:\/\/doi.org\/10.1016\/0002-9343(89)90010-7","journal-title":"Am J Med"},{"key":"11311_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1086\/600122","volume":"200","author":"B Fantin","year":"2009","unstructured":"Fantin B, Duval X, Massias L et al (2009) Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 200:390\u2013398. https:\/\/doi.org\/10.1086\/600122","journal-title":"J Infect Dis"},{"key":"11311_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2005.02.037","volume":"140","author":"JM Burka","year":"2005","unstructured":"Burka JM, Bower KS, Vanroekel RC et al (2005) The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. Am J Ophthalmol 140:83\u201387. https:\/\/doi.org\/10.1016\/j.ajo.2005.02.037","journal-title":"Am J Ophthalmol"},{"key":"11311_CR45","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S13778","author":"F Mah","year":"2011","unstructured":"Mah F, Cervantes, (2011) Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. Clin Ophthalmol. https:\/\/doi.org\/10.2147\/OPTH.S13778","journal-title":"Clin Ophthalmol"},{"key":"11311_CR46","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2165\/00003495-198530060-00003","volume":"30","author":"B Holmes","year":"1985","unstructured":"Holmes B, Brogden RN, Richards DM (1985) Norfloxacin a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 30:482\u2013513. https:\/\/doi.org\/10.2165\/00003495-198530060-00003","journal-title":"Drugs"},{"key":"11311_CR47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0002-9343(87)90626-7","volume":"82","author":"PNR Heseltine","year":"1987","unstructured":"Heseltine PNR, Corrado ML (1987) Compassionate use of norfloxacin. Am J Med 82:88\u201392. https:\/\/doi.org\/10.1016\/0002-9343(87)90626-7","journal-title":"Am J Med"},{"key":"11311_CR48","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2165\/00003495-198733040-00003","volume":"33","author":"JP Monk","year":"1987","unstructured":"Monk JP, Campoli-Richards DM (1987) Ofloxacin. Drugs 33:346\u2013391. https:\/\/doi.org\/10.2165\/00003495-198733040-00003","journal-title":"Drugs"},{"key":"11311_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.curtheres.2003.11.003","volume":"64","author":"P Ball","year":"2003","unstructured":"Ball P (2003) Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Curr Ther Res 64:646\u2013661. https:\/\/doi.org\/10.1016\/j.curtheres.2003.11.003","journal-title":"Curr Ther Res"},{"key":"11311_CR50","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.clinthera.2010.09.004","volume":"32","author":"J Figueira-Coelho","year":"2010","unstructured":"Figueira-Coelho J, Pereira O, Picado B, Mendon\u00e7a P, Neves-Costa J, Neta J (2010) Acute hepatitis associated with the use of levofloxacin. Clin Ther 32:1733\u20131737. https:\/\/doi.org\/10.1016\/j.clinthera.2010.09.004","journal-title":"Clin Ther"},{"key":"11311_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2165\/00003088-199325050-00002","volume":"25","author":"J Shimada","year":"1993","unstructured":"Shimada J, Nogita T, Ishibashi Y (1993) Clinical pharmacokinetics of Sparfloxacin. Clin Pharmacokinet 25:358\u2013369. https:\/\/doi.org\/10.2165\/00003088-199325050-00002","journal-title":"Clin Pharmacokinet"},{"key":"11311_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1469-0691.1998.tb00376.x","volume":"4","author":"H Lode","year":"1998","unstructured":"Lode H, Aubier M, Portier H, Ortqvist A (1998) Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia. Clin Microbiol Infect 4:135\u2013143. https:\/\/doi.org\/10.1111\/j.1469-0691.1998.tb00376.x","journal-title":"Clin Microbiol Infect"},{"key":"11311_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000057838","volume":"47","author":"E Rubinstein","year":"2001","unstructured":"Rubinstein E (2001) History of quinolones and their side effects. Chemotherapy 47:3\u20138. https:\/\/doi.org\/10.1159\/000057838","journal-title":"Chemotherapy"},{"key":"11311_CR54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1128\/AAC.39.2.513","volume":"39","author":"J Child","year":"1995","unstructured":"Child J, Andrews JM, Wise R (1995) Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob Agents Chemother 39:513\u2013515. https:\/\/doi.org\/10.1128\/AAC.39.2.513","journal-title":"Antimicrob Agents Chemother"},{"key":"11311_CR55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jac\/44.4.515","volume":"44","author":"CE Langan","year":"1999","unstructured":"Langan CE, Zuck P, Vogel F et al (1999) Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 44:515\u2013523. https:\/\/doi.org\/10.1093\/jac\/44.4.515","journal-title":"J Antimicrob Chemother"},{"key":"11311_CR56","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0959-8049(02)80607-4","volume":"38","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Silberman S, Dimitrijevic S (2002) Imatinib: the first 3 years. Eur J Cancer 38:S77\u2013S82. https:\/\/doi.org\/10.1016\/S0959-8049(02)80607-4","journal-title":"Eur J Cancer"},{"key":"11311_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/357027","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Imatinib: A Breakthrough of Targeted Therapy in Cancer. Chemother Res Pract 2014:1\u20139. https:\/\/doi.org\/10.1155\/2014\/357027","journal-title":"Chemother Res Pract"},{"key":"11311_CR58","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.2147\/DDDT.S85050","volume":"10","author":"D Keskin","year":"2016","unstructured":"Keskin D, Sadri S, Eskazan AE (2016) Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Des Devel Ther 10:3355\u20133361. https:\/\/doi.org\/10.2147\/DDDT.S85050","journal-title":"Drug Des Devel Ther"},{"key":"11311_CR59","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00023210-200923050-00006","volume":"23","author":"KF Croom","year":"2009","unstructured":"Croom KF, Perry CM, Plosker GL (2009) Mirtazapine. CNS Drugs 23:427\u2013452. https:\/\/doi.org\/10.2165\/00023210-200923050-00006","journal-title":"CNS Drugs"},{"key":"11311_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4068\/cmj.2016.52.2.91","volume":"52","author":"S-M Wang","year":"2016","unstructured":"Wang S-M, Han C, Lee S-J et al (2016) Vilazodone for the treatment of depression: an update. Chonnam Med J 52:91. https:\/\/doi.org\/10.4068\/cmj.2016.52.2.91","journal-title":"Chonnam Med J"},{"key":"11311_CR61","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","volume":"11","author":"ZT Sahli","year":"2016","unstructured":"Sahli ZT, Banerjee P, Tarazi FI (2016) The preclinical and clinical effects of Vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov 11:515\u2013523. https:\/\/doi.org\/10.1517\/17460441.2016.1160051","journal-title":"Expert Opin Drug Discov"},{"key":"11311_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2019.127422","volume":"1203","author":"M Y\u0131ld\u0131z","year":"2020","unstructured":"Y\u0131ld\u0131z M (2020) Design, synthesis, characterization, and antimicrobial activity of novel piperazine substituted 1,4-benzoquinones. J Mol Struct 1203:127422. https:\/\/doi.org\/10.1016\/j.molstruc.2019.127422","journal-title":"J Mol Struct"},{"key":"11311_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104398","volume":"105","author":"G-Y Zhang","year":"2020","unstructured":"Zhang G-Y, Zhang Z, Li K et al (2020) Design, synthesis and biological evaluation of novel pleuromutilin derivatives containing piperazine and 1,2,3-triazole linker. Bioorg Chem 105:104398. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104398","journal-title":"Bioorg Chem"},{"key":"11311_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112604","volume":"204","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Li K, Zhang G-Y et al (2020) Design, synthesis and biological activities of novel pleuromutilin derivatives with a substituted triazole moiety as potent antibacterial agents. Eur J Med Chem 204:112604. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112604","journal-title":"Eur J Med Chem"},{"key":"11311_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114398","volume":"237","author":"R Ding","year":"2022","unstructured":"Ding R, Wang X, Fu J et al (2022) Design, synthesis and antibacterial activity of novel pleuromutilin derivatives with thieno[2,3-d]pyrimidine substitution. Eur J Med Chem 237:114398. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114398","journal-title":"Eur J Med Chem"},{"key":"11311_CR66","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1080\/14756366.2022.2104267","volume":"37","author":"Q Wang","year":"2022","unstructured":"Wang Q, Liu J, Zhou Z-D et al (2022) Design, synthesis, biological evaluation and molecular docking studies of novel pleuromutilin derivatives containing nitrogen heterocycle and alkylamine groups. J Enzyme Inhib Med Chem 37:2078\u20132091. https:\/\/doi.org\/10.1080\/14756366.2022.2104267","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11311_CR67","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1002\/jhet.4099","volume":"57","author":"RR Shinde","year":"2020","unstructured":"Shinde RR, Gaikwad D, Farooqui M (2020) Synthesis and antimicrobial activity of 2-(4-(benzo[d]thiazol-5-ylsulfonyl)piperazine-1-yl)-N-substituted acetamide derivatives. J Heterocycl Chem 57:3907\u20133917. https:\/\/doi.org\/10.1002\/jhet.4099","journal-title":"J Heterocycl Chem"},{"key":"11311_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104164","volume":"104","author":"YA Ammar","year":"2020","unstructured":"Ammar YA, Farag AA, Ali AM et al (2020) Design, synthesis, antimicrobial activity and molecular docking studies of some novel di-substituted sulfonylquinoxaline derivatives. Bioorg Chem 104:104164. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104164","journal-title":"Bioorg Chem"},{"key":"11311_CR69","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1002\/slct.202101194","volume":"6","author":"R Heiran","year":"2021","unstructured":"Heiran R, Jarrahpour A, Riazimontazer E, Gholami A, Troudi A, Digiorgio C et al (2021) Sulfonamide-\u03b2-lactam hybrids incorporating the piperazine moiety as potential antiinflammatory agent with promising antibacterial activity. ChemSelect 6:5313\u20135319. https:\/\/doi.org\/10.1002\/slct.202101194","journal-title":"ChemSelect"},{"key":"11311_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.130168","volume":"1234","author":"S Malasala","year":"2021","unstructured":"Malasala S, Polomoni A, Ahmad MN, Shukla M, Kaul G, Dasgupta A et al (2021) Structure based design, synthesis and evaluation of new thienopyrimidine derivatives as anti-bacterial agents. J Mol Struct 1234:130168. https:\/\/doi.org\/10.1016\/j.molstruc.2021.130168","journal-title":"J Mol Struct"},{"key":"11311_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.131333","volume":"1247","author":"HSN Prasad","year":"2022","unstructured":"Prasad HSN, Ananda AP, Lohith TN et al (2022) Design, synthesis, molecular docking and DFT computational insight on the structure of Piperazine sulfynol derivatives as a new antibacterial contender against superbugs MRSA. J Mol Struct 1247:131333. https:\/\/doi.org\/10.1016\/j.molstruc.2021.131333","journal-title":"J Mol Struct"},{"key":"11311_CR72","doi-asserted-by":"publisher","unstructured":"Gnanavelu K, K. S. VK, Eswaran S, Sivashanmugam K (2023) Novel quinoline-piperazine hybrids: the design, synthesis and evaluation of antibacterial and antituberculosis properties. RSC Med Chem 14:183\u2013189. https:\/\/doi.org\/10.1039\/D2MD00260D","DOI":"10.1039\/D2MD00260D"},{"key":"11311_CR73","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/00397911.2024.2320856","volume":"54","author":"JT Kilbile","year":"2024","unstructured":"Kilbile JT, Akber Ansari S, Gadekar SS et al (2024) Design, synthesis, and molecular docking study of N -(arylsulfonyl)- l -proline-piperazine hybrids tethered with pyrazole\/benzofuran moiety as antimicrobial agents. Synth Commun 54:567\u2013582. https:\/\/doi.org\/10.1080\/00397911.2024.2320856","journal-title":"Synth Commun"},{"key":"11311_CR74","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1080\/00397911.2022.2132868","volume":"52","author":"P Yadav","year":"2022","unstructured":"Yadav P, Kaushik CP, Kumar A (2022) Synthesis and antimicrobial activity of piperazine containing substituted 1,2,3-triazoles with amide linkage. Synth Commun 52:2149\u20132162. https:\/\/doi.org\/10.1080\/00397911.2022.2132868","journal-title":"Synth Commun"},{"key":"11311_CR75","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.3390\/molecules28145562","volume":"28","author":"S Janowska","year":"2023","unstructured":"Janowska S, Andrzejczuk S, Gawry\u015b P, Wujec M (2023) Synthesis and antimicrobial activity of new mannich bases with piperazine moiety. Molecules 28:5562. https:\/\/doi.org\/10.3390\/molecules28145562","journal-title":"Molecules"},{"key":"11311_CR76","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/jhet.3791","volume":"57","author":"HR Bhat","year":"2020","unstructured":"Bhat HR, Masih A, Shakya A et al (2020) Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4-aminoquinoline-1,3,5-triazine derivatives. J Heterocycl Chem 57:390\u2013399. https:\/\/doi.org\/10.1002\/jhet.3791","journal-title":"J Heterocycl Chem"},{"key":"11311_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114747","volume":"243","author":"S Dinesh Kumar","year":"2022","unstructured":"Dinesh Kumar S, Park JH, Kim HS et al (2022) Cationic, amphipathic small molecules based on a triazine-piperazine-triazine scaffold as a new class of antimicrobial agents. Eur J Med Chem 243:114747. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114747","journal-title":"Eur J Med Chem"},{"key":"11311_CR78","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40199-020-00373-6","volume":"28","author":"M Norouzbahari","year":"2020","unstructured":"Norouzbahari M, Salarinejad S, G\u00fcran M et al (2020) Design, synthesis, molecular docking study, and antibacterial evaluation of some new fluoroquinolone analogues bearing a quinazolinone moiety. DARU J Pharm Sci 28:661\u2013672. https:\/\/doi.org\/10.1007\/s40199-020-00373-6","journal-title":"DARU J Pharm Sci"},{"key":"11311_CR79","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/ph14050399","volume":"14","author":"LH Al-Wahaibi","year":"2021","unstructured":"Al-Wahaibi LH, Amer AA, Marzouk AA et al (2021) Design, synthesis, and antibacterial screening of some novel heteroaryl-based ciprofloxacin derivatives as DNA gyrase and topoisomerase IV inhibitors. Pharmaceuticals 14:399. https:\/\/doi.org\/10.3390\/ph14050399","journal-title":"Pharmaceuticals"},{"key":"11311_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.134013","volume":"1271","author":"S Jagadeesan","year":"2023","unstructured":"Jagadeesan S, Karpagam S (2023) Novel series of N-acyl substituted indole based piperazine, thiazole and tetrazoles as potential antibacterial, antifungal, antioxidant and cytotoxic agents, and their docking investigation as potential Mcl-1 inhibitors. J Mol Struct 1271:134013. https:\/\/doi.org\/10.1016\/j.molstruc.2022.134013","journal-title":"J Mol Struct"},{"key":"11311_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129320","volume":"89","author":"T Liu","year":"2023","unstructured":"Liu T, Yao X, Zhang R et al (2023) Design, synthesis and biological evaluation of novel indole-piperazine derivatives as antibacterial agents. Bioorg Med Chem Lett 89:129320. https:\/\/doi.org\/10.1016\/j.bmcl.2023.129320","journal-title":"Bioorg Med Chem Lett"},{"key":"11311_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2023.100951","volume":"5","author":"S Rejinthala","year":"2023","unstructured":"Rejinthala S, Endoori S, Vemula D et al (2023) Novel pyrimidine-piperazine hybrids as potential antimicrobial agents: in-vitro antimicrobial and in-silico studies. Results Chem 5:100951. https:\/\/doi.org\/10.1016\/j.rechem.2023.100951","journal-title":"Results Chem"},{"key":"11311_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104060","volume":"102","author":"S Pospisilova","year":"2020","unstructured":"Pospisilova S, Malik I, Curillova J et al (2020) Insight into antimicrobial activity of substituted phenylcarbamoyloxypiperazinylpropanols. Bioorg Chem 102:104060. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104060","journal-title":"Bioorg Chem"},{"key":"11311_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.130047","volume":"1232","author":"HSN Prasad","year":"2021","unstructured":"Prasad HSN, Ananda AP, Najundaswamy S et al (2021) Design, synthesis and molecular docking studies of novel piperazine metal complexes as potential antibacterial candidate against MRSA. J Mol Struct 1232:130047. https:\/\/doi.org\/10.1016\/j.molstruc.2021.130047","journal-title":"J Mol Struct"},{"key":"11311_CR85","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11030-021-10190-x","volume":"26","author":"M Patil","year":"2022","unstructured":"Patil M, Noonikara-Poyil A, Joshi SD et al (2022) Synthesis, molecular docking studies, and in vitro antimicrobial evaluation of piperazine and triazolo-pyrazine derivatives. Mol Divers 26:827\u2013841. https:\/\/doi.org\/10.1007\/s11030-021-10190-x","journal-title":"Mol Divers"},{"key":"11311_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1760134","author":"M Erol","year":"2020","unstructured":"Erol M, Celik I, Temiz-Arpaci O et al (2020) Design, synthesis, molecular docking, density functional theory and antimicrobial studies of some novel benzoxazole derivatives as structural bioisosteres of nucleotides. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1760134","journal-title":"J Biomol Struct Dyn"},{"key":"11311_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116202","volume":"246","author":"MA Acquavia","year":"2024","unstructured":"Acquavia MA, Bonomo MG, Bianco G et al (2024) New piperazine and morpholine derivatives: mass spectrometry characterization and evaluation of their antimicrobial activity. J Pharm Biomed Anal 246:116202. https:\/\/doi.org\/10.1016\/j.jpba.2024.116202","journal-title":"J Pharm Biomed Anal"},{"key":"11311_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000208","author":"S Sirakanyan","year":"2021","unstructured":"Sirakanyan S, Kartsev V, Spinelli D et al (2021) Synthesis and antimicrobial activity of new 2-piperazin-1-yl-N-1,3-thiazol-2-ylacetamides of cyclopenta[c]pyridines and pyrano[3,4-c]pyridines. Arch Pharm (Weinheim). https:\/\/doi.org\/10.1002\/ardp.202000208","journal-title":"Arch Pharm (Weinheim)"},{"key":"11311_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.134755","volume":"1276","author":"KB Patel","year":"2023","unstructured":"Patel KB, Mukherjee S, Bhatt H et al (2023) Synthesis, docking, and biological investigations of new coumarin-piperazine hybrids as potential antibacterial and anticancer agents. J Mol Struct 1276:134755. https:\/\/doi.org\/10.1016\/j.molstruc.2022.134755","journal-title":"J Mol Struct"},{"key":"11311_CR90","doi-asserted-by":"publisher","DOI":"10.2174\/0115734072265828231010050909","author":"NB Patel","year":"2024","unstructured":"Patel NB, Maisuria PN, Gujarati AV, Patel DK (2024) Synthesis of piperazine-containing derivatives and their antimicrobial, antimycobacterial, antimalarial and antioxidant activities. Curr Bioact Compd. https:\/\/doi.org\/10.2174\/0115734072265828231010050909","journal-title":"Curr Bioact Compd"},{"key":"11311_CR91","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1039\/D1MD00230A","volume":"12","author":"I Saleh","year":"2021","unstructured":"Saleh I, Raj KCH, Roy S et al (2021) Design, synthesis, and antibacterial activity of N -(trifluoromethyl)phenyl substituted pyrazole derivatives. RSC Med Chem 12:1690\u20131697. https:\/\/doi.org\/10.1039\/D1MD00230A","journal-title":"RSC Med Chem"},{"key":"11311_CR92","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/cbdd.13803","volume":"97","author":"G Mazur","year":"2021","unstructured":"Mazur G, Skiba-Kurek I, Karczewska E et al (2021) Design, synthesis and activity against Staphylococcus epidermidis of 5-chloro-2- or 5-chloro-4-methyl-9 H -xanthen-9-one and some of its derivatives. Chem Biol Drug Des 97:674\u2013685. https:\/\/doi.org\/10.1111\/cbdd.13803","journal-title":"Chem Biol Drug Des"},{"key":"11311_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.132082","volume":"1252","author":"M Rani","year":"2022","unstructured":"Rani M, Jayanthi S, Kabilan S, Ramachandran R (2022) Synthesis, spectral, crystal structure, Hirshfeld surface, computational analysis, and antimicrobial studies of ethyl-(E)-4-(2-(2-arylidenehydrazinyl)-2-oxoethyl)piperazine-1-carboxylates. J Mol Struct 1252:132082. https:\/\/doi.org\/10.1016\/j.molstruc.2021.132082","journal-title":"J Mol Struct"},{"key":"11311_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.132260","volume":"1253","author":"Y Narasimha Reddy","year":"2022","unstructured":"Narasimha Reddy Y, Reddy Mardi R, Reddy GN et al (2022) One-pot synthesis of novel substituted quinoxaline piperazine derivatives and their antimicrobial activities. J Mol Struct 1253:132260. https:\/\/doi.org\/10.1016\/j.molstruc.2021.132260","journal-title":"J Mol Struct"},{"key":"11311_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105568","volume":"119","author":"B Mekonnen Sanka","year":"2022","unstructured":"Mekonnen Sanka B, Mamo Tadesse D, Teju Bedada E et al (2022) Design, synthesis, biological screening and molecular docking studies of novel multifunctional 1,4-di (aryl\/heteroaryl) substituted piperazine derivatives as potential antitubercular and antimicrobial agents. Bioorg Chem 119:105568. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105568","journal-title":"Bioorg Chem"},{"key":"11311_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdc.2022.100862","volume":"39","author":"AR Zala","year":"2022","unstructured":"Zala AR, Rajani DP, Kumari P (2022) Design, synthesis, molecular docking and antimicrobial and antimycobacterial activities of novel hybrid of coumarin-cinnamic acids. Chem Data Collect 39:100862. https:\/\/doi.org\/10.1016\/j.cdc.2022.100862","journal-title":"Chem Data Collect"},{"key":"11311_CR97","doi-asserted-by":"publisher","first-page":"54","DOI":"10.33263\/LIANBS122.054","volume":"12","author":"HSN Prasad","year":"2022","unstructured":"Prasad HSN, Gaonkar NP, Ananda AP, Mukarambi A, Kumar GCLT (2022) Antibacterial property of Schiff-based Piperazine against MRSA: design, synthesis, molecular docking, and DFT computational studies. Lett Appl NanoBioScience 12:54. https:\/\/doi.org\/10.33263\/LIANBS122.054","journal-title":"Lett Appl NanoBioScience"},{"key":"11311_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09564","volume":"8","author":"AZ Halimehjani","year":"2022","unstructured":"Halimehjani AZ, Dehghan F, Tafakori V et al (2022) Synthesis of novel antibacterial and antifungal dithiocarbamate-containing piperazine derivatives via re-engineering multicomponent approach. Heliyon 8:e09564. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09564","journal-title":"Heliyon"},{"key":"11311_CR99","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/molecules27030803","volume":"27","author":"EM Mohi El-Deen","year":"2022","unstructured":"Mohi El-Deen EM, Anwar MM, El-Gwaad AAA et al (2022) Novel pyridothienopyrimidine derivatives: design, synthesis and biological evaluation as antimicrobial and anticancer agents. Molecules 27:803. https:\/\/doi.org\/10.3390\/molecules27030803","journal-title":"Molecules"},{"key":"11311_CR100","doi-asserted-by":"publisher","first-page":"20","DOI":"10.54287\/gujsa.1213307","volume":"10","author":"SM Muhammet","year":"2023","unstructured":"Muhammet SM (2023) Design, DFT calculations and antimicrobial activity of new synthesized piperazine derivative. Gazi Univ J Sci Part A Eng Innov 10:20\u201329. https:\/\/doi.org\/10.54287\/gujsa.1213307","journal-title":"Gazi Univ J Sci Part A Eng Innov"},{"key":"11311_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135791","volume":"1289","author":"YU Cebeci","year":"2023","unstructured":"Cebeci YU, Batur \u00d6\u00d6, Boulebd H (2023) New piperazine-hydrazone derivatives as potential antimicrobial agents: synthesis, characterization, biological evaluation, and in silico investigations. J Mol Struct 1289:135791. https:\/\/doi.org\/10.1016\/j.molstruc.2023.135791","journal-title":"J Mol Struct"},{"key":"11311_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2023.101237","volume":"7","author":"D Singh","year":"2024","unstructured":"Singh D, Patel R, Aggarwal A et al (2024) Phenylthiazolidin-4-one piperazine conjugates: design, synthesis, anticancer and antimicrobial studies. Results Chem 7:101237. https:\/\/doi.org\/10.1016\/j.rechem.2023.101237","journal-title":"Results Chem"},{"key":"11311_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101684","volume":"10","author":"IMZ Fares","year":"2024","unstructured":"Fares IMZ, Mahmoud NE, Abdelhamid IA et al (2024) Synthesis, molecular docking simulation, and antimicrobial activities of novel bis-heterocycles linked to piperazine and vanillin units as novel hybrid molecules via Hantzsch, Biginelli, and Michael\u2019s reactions. Results Chem 10:101684. https:\/\/doi.org\/10.1016\/j.rechem.2024.101684","journal-title":"Results Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11311-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11311-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11311-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:34:00Z","timestamp":1779536040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11311-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":103,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["11311"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11311-6","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that they have no financial interests or personal relationships that could be seen as influencing the work presented in this manuscript. They also state that there are no conflicts of interest. This manuscript is original, has not been published previously, and is not under consideration for publication elsewhere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}